This week’s episode of “The Readout LOUD” discusses the potential activist investor campaign against Pfizer and the impact on the pharmaceutical giant. Experts are questioning regulatory standards for gene therapies for Duchenne muscular dystrophy. The difference between Novo Holdings and Novo Nordisk is explored in relation to a $16 billion acquisition of Catalent. The episode also delves into Robert F. Kennedy Jr. and the Make America Healthy Again movement. Topics covered include Pfizer’s gene therapy failures, Novo Holdings’ controversial acquisitions, and Kennedy’s influence on the Republican health care agenda. The episode can be listened to on Apple Podcasts, Spotify, and other platforms.
Source link
Pfizer’s activist troubles, gene therapy questions, RFK Jr.’s MAHA ambitions
